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Purpose: To investigate the feasibility of neoadjuvant chemotherapy and replanning intensity-modulated
radiotherapy (IMRT) for intracranial invasion nasopharyngeal carcinoma (NPC).
Methods and materials: From June 2007 to January 2012, 32 patients with intracranial invasion NPC treated with
TPF (docetaxel 75 mg/m2, cisplatin 75 mg/m2, 5-FU 2500 mg/m2 every 3 weeks for 3 cycles) neoadjuvant
chemotherapy, and replanning IMRT with concurrent chemotherapy were retrospectively studied. The first IMRT
plan for each patient was generated based on the original planning CT scan acquired before the start of treatment.
Because of tumor shrinkage during radiotherapy, modified gross tumor volume of primary tumor (GTV-P) and high
risk clinical target volume (CTV-H), and a new plan was generated and used to complete the course of IMRT. The
DVHs of IMRT plan with or without replanning were compared.
Results: There weren’t statistically significant differences in the V95, D-mean, D-95, and D-99 to the modified
PTVGTV-P and PTVCTV-H with and without replanning IMRT. Replanning reduced the doses to the brain stem, optic
nerve, optic chiasm and temporal lobe. Objective responses were 100.0% 3 months after completion of
radiotherapy. Acute toxicities were well tolerated, except for the relatively high incidence of neutropenia. The 2-year
local control rates and distant-metastasis free survival were 88.2% (95% CI, 72.9% to 100.0%) and 89.6% (95% CI,
75.9% to 100.0%).
Conclusion: Neoadjuvant chemotherapy and replanning IMRT according to tumor shrinkage during the treatment is
essential to ensure safe doses to normal tissues, and produces encouraging outcome for intracranial invasion NPC.
Keywords: Nasopharyngeal carcinoma, Replanning IMRT, Comprehensive treatmentIntroduction
Radiation therapy (RT) is the mainstay of definitive ther-
apy for nonmetastatic nasopharyngeal carcinoma (NPC).
New radiotherapy technique, intensity-modulated radio-
therapy (IMRT) has allowed improved dose delivery to
NPC tumors while reducing dose to normal tissues [1-4].
However, for patients with intracranial invasion NPC, a
common problem encounters in planning IMRT is that
the vital structures (such as brain stem, optic nerve, chi-
asm) are in close proximity to the tumor volumes, which* Correspondence: konglinj@gmail.com
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reproduction in any medium, provided the orcreates a dilemma in dose optimization as the region of
overlap between the target and the normal tissues [5-10].
NPC is sensitive to chemotherapy. Neoadjuvant chemo-
therapy has potential advantages of shrinking the tumor
bulk before irradiation, as a result narrowing down the
tumor target area facilitating the radiotherapy particularly
for patients with extensive local infiltration adjacent to
critical neurologic structures. The response rate (76.5% ~
82.0%) of NPC after neoadjuvant chemotherapy with vari-
ous regimens was reported [11,12]. Furthermore, it was
reported [13] the volume of primary tumor declined in
70% ± 4.8% patients after 45 Gy of radiation, which
allowed potential target volume and/or dose modification. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ing the course of IMRT may have potential advantages to
ensure adequate doses to target volumes and safe doses to
normal tissues.
To maximize local control of the tumor and spare the
adjacent critical neurologic structures for this group NPC
patient with intracranial invasion, from June 2007, we
used neoadjuvant chemotherapy and replanning IMRT for
32 patients with intracranial invasion NPC. This study in-
vestigates the dosimetric effects of replanning during the
course of IMRT on both normal tissues and target vol-




From June 2007 to January 2012, 32 patients with intracra-
nial invasion NPC treated with neoadjuvant chemotherapy
and replanning IMRT with concurrent chemotherapy
were studied. The disease was staged according to the
2002 American Joint Committee on Cancer (AJCC) sta-
ging classifications. Biopsy at the primary site is required
for all patients for pathologic diagnosis. Pretreatment sta-
ging evaluations included clinical examination of the head
and neck, MRI scans of the head and neck, CT scan of the
thorax, whole-body bone scan, abdominal sonography,
complete blood count, and serum biochemical profile.
Chemotherapy
All patients were treated with TPF (docetaxel 75 mg/m2,
cisplatin 75 mg/m2, 5-FU 2500 mg/m2 every 3 weeks for
3 cycles) neoadjuvant chemotherapy, and replanning
IMRT with concurrent chemotherapy. Dose modifications
were based on the preceding cycle nadir blood counts and
interim toxic effects. A reduction of dosage of docetaxel
by 20% with constant cisplatin and 5FU dosages was
allowed if a grade IV hematology adverse event or febrile
neutropenia emerged in the previous course. All of the
dosages of docetaxel, cisplatin, and 5FU were decreased by
20% if more than grade III mucositis or diarrhea happened
in the former course.
Concurrent chemotherapy consisted of weekly cisplatin
(40 mg/m 2) during radiotherapy for a maximum of six cy-
cles, beginning on the first day of radiotherapy as planned.
Chemotherapy at the full dose was delivered strictly. The
chemotherapy time was postponed if neutropil <2000/lL or
platelets < 100,000/lL and suspended if the creatinine clear-
ance rate became < 50 mL/min.
Radiotherapy and treatment planning
Before treatment, all the patients were immobilized with
a thermoplastic head and shoulder mask, and CT simu-
lation according to standard procedures. The CT scan
was performed after the completion of neoadjuvantchemotherapy using 0.3 cm slice spacing through the
region that contained the primary target volumes, and
0.5 cm through the regions above and below the target
volume. Magnetic resonance scans and fusion with
simulation CT images were performed to assist the tar-
gets delineation.
All patients were treated with IMRT definitively. The
details of the tumor volume delineation have been detailed
previously [14]. The doses prescribed to PTVGTV-P,
PTVGTV-N and PTVCTV-H was 70 Gy, 68.25/66.50 Gy, and
61.25 Gy (in 35 fractions). The low neck or supraclavicular
field (PTVCTV-L) was treated with AP/PA fields and re-
ceived 30 fractions of 1.8 Gy/fraction, for a total of 54 Gy.
Radiotherapy was delivered once daily, 5 fractions per
week, over 7 weeks.
When there was a safe margin between the target and
the critical normal tissues (e.g. brain stem), the outlined of
the GTV (GTV-P1) and CTV-H (CTV-H1) were mainly
based on the enhanced MRI before the neoadjuvant
chemotherapy; otherwise, the enhanced MRI after the
neoadjuvant chemotherapy. The doses prescribed to
PTVGTV-P1, and PTVCTV-H1 was 56 Gy and 49 Gy (in 28
fractions). Inverse planning was used. Before the 23th frac-
tion of IMRT, a new nasopharyngeal enhanced MRI ac-
quired for all patients. GTV-P and CTV-H were modified
based on the tumor shrinkage shown on the new nasopha-
ryngeal enhanced MRI and reoutlined on the original CT
simulation scan. Replanning was performed and the doses
prescribed to new PTVGTV-P2 and PTVCTV-H2 was 14 Gy
and 12.25 Gy (in 7 fractions). GTV-LN and CTV-L were
not changed. All plans were created on the Pinnacle. For
all plans, 7–9 coplanar 6-MV photon beams were evenly
distributed around the patient’s head and neck. Examples
of contoured PTVGTV-P2 and PTVCTV-H2 were presented
in Figures 1 and 2.
Volume and dosimetric comparisons
Target volumes (PTVGTV-P1 vs. PTVGTV-P2; PTVCTV-H1 vs.
PTVCTV-H2) were compared with a paired samples analysis.
For each IMRT plan, dose–volume histograms (DVHs)
were calculated for target volumes and normal structures.
DVHs of target volumes and all sensitive structures were
characterized by multiple endpoints. The endpoints of
PTVGTV-P and PTVCTV-H were the mean dose and the
doses encompassing 95% (D-95) and 99% (D-99) of the vol-
umes. To reflect the characteristics of DVHs in high dose
regions for serial structures including the brainstem, optic
chiasm and optic nerves, we chose three endpoints that
were the maximum dose, the doses encompassing 5% and
10% of the volumes. For sensitive structures with functional
subunit in parallel such as the temporal lobe, inner and
middle ear, the mean dose and the doses encompassing
50% and 80% of the volumes were chosen as endpoints.
The DVHs of IMRT plan with replanning were compared
Figure 1 An example of the contour of the PTVGTV-P. The aubergine shadow represented the PTVGTV-P1 and the blue line was PTVGTV-P2. The
margin between tumor and critical normal was extended.
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samples t test. A value of p < 0.05 was considered statisti-
cally significant.
Statistical analysis
The Statistical Package for the Social Science (SPSS for Win-
dows 16.0; SPSS Inc., Chicago, IL) was used for statistical
analysis. Descriptive statistics were used to summarize the
patient characteristics. The estimated overall survival (OS),
disease progression-free survival (PFS), local progression-free
survival (LPFS), regional progression-free survival (RPFS),
and distant metastasis-free survival (DMFS) were calculated
by the Kaplan-Meier method. Adverse events were evaluated
according to the National Cancer Institute’s Common Ter-
minology Criteria for Adverse Events (NCI CTCAE 3.0). The
duration of survival was measured from the time of patho-
logical diagnosis until death or the date of the last follow-up
visit for patients still alive.
Follow-up
After the completion of concurrent chemoradiation, all
patients were assessed every 3 months during the first3 years, every 6 months for the next 2 years, and annu-
ally thereafter. All local recurrences were diagnosed with
nasopharyngoscopy and biopsy, MRI of the head and
neck. Regional recurrences were diagnosed by clinical
examination of the neck and, in doubtful cases, by fine
needle aspiration or an MRI scan of the neck. Distant
metastases were diagnosed by clinical symptoms, physical ex-
aminations, and imaging methods. Whenever necessary and
possible, salvage treatments including re-irradiation, chemo-
therapy, and surgery, was provided to patients with relapse.
Results
Patient characteristics
From June 2007 to January 2012, 32 patients (median,
48 years; range, 20-66 years) with intracranial invasion
NPC treated with replanning IMRT were analyzed for this
research. All patients were treated with neoadjuvant
chemotherapy and concurrent chemoradiotherapy. The
median follow-up was 19.5 months (range 8.0–63.0). Of the
32 patients, 24 were male and 8 were female (male:female
ratio, 3:1) and 7 were in N0, 9 were in N1, 12 were in N2,
and 4 were in N3.
Figure 2 An example of the contour of the PTVCTV-H. The green shadow represented the PTVCTV-H1 and the blue line was PTVCTV-H2. The
margin between tumor and critical normal was extended.
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Volumetric changes and dosimetry comparisons of
target volumes
The mean volume of PTVGTV-P2 (116.09 ± 37.69 cc) de-
creased significantly (p = 0.000), compared with PTVGTV-P1
(102.92 ± 30.64 cc). The mean volume to the PTVCTV-H1
and PTVCTV-H2 were 509.36 ± 143.09 cc and 486.62 ±
136.84 cc (p = 0.000), respectively.
For both the PTVGTV-P2 and the PTVCTV-H2, the
mean dose, D-95, D-99, and V95 (percent of volume
receiving ≥95% of the prescribed dose) were not differ-
ent between replanning and not replanning (Table 1).
The differences were significant for both the PTVGTV-P1
and the PTVCTV-H1 as we expected (Table 1).
Dosimetry comparisons of normal tissues
Serial structures
Among the serial-sensitive structures evaluated, replan-
ning reduced the dose of brain stem, optic nerve and optic
chiasm (Table 2). There was a significant decrease with
the replanning IMRT plan in the dose delivered to the
brain stem when analyzed by doses encompassing 5% of
the volume (p = 0.001) and 10% of the volume (p = 0.023).The D-1, D-5 and D-10 of the brain stem decreased with
replanning. There were significantly different between the
replanning and without replanning in the endpoint doses
(the maximum dose, the doses encompassing 5% and 10%
of the volume) to the chiasm and the optic nerve for each
of the endpoints considered (all p = 0.000).
Parallel structures
In comparison between the replanning and without re-
planning IMRT plans for parallel sensitive structures,
there were statistical differences to temporal lobe for each
of the endpoints considered (the maximum dose, the
doses encompassing 50% and 80% of the volume), as well
as the middle ear and inner ear. The details of the com-
parison of average endpoint doses for selected parallel
structure were shown in Table 2.Treatment outcomes
Response of disease
Objective responses were 93.7% (CR 15.6%) and 100% (CR
12%) to the primary tumor and cervical lymph nodes after
neoadjuvant chemotherapy, the corresponding rates were
Table 1 Dosimetry comparisons of target volumes
Variable Replanned Not replanned P value Variable Replanned Not replanned P value
PTVGTV-P1 PTVGTV-P2
D-mean (Gy) 71.86 ± 0.88 72.05 ± 0.98 0.000 D-mean (Gy) 72.29 ± 1.11 72.32 ± 1.07 0.394
D-95 (Gy) 67.15 ± 2.30 68.17 ± 1.68 0.000 D-95 (Gy) 69.41 ± 1.38 69.28 ± 1.19 0.276
D-99 (Gy) 63.52 ± 3.59 65.64 ± 2.08 0.000 D-99 (Gy) 67.29 ± 1.62 67.16 ± 1.50 0.463
V95 (%) 96.29 ± 3.07 97.42 ± 2.50 0.000 V95 (%) 99.20 ± 1.52 99.66 ± 2.47 0.208
PTVCTV-H1 PTVCTV-H2
D-mean (Gy) 66.54 ± 1.37 66.70 ± 1.40 0.363 D-mean (Gy) 66.65 ± 1.17 66.82 ± 1.40 0.184
D-95 (Gy) 60.35 ± 1.35 61.26 ± 1.80 0.015 D-95 (Gy) 61.15 ± 1.18 61.43 ± 1.79 0.435
D-99 (Gy) 55.36 ± 3.17 58.20 ± 2.82 0.000 D-99 (Gy) 58.10 ± 2.65 58.54 ± 2.76 0.284
V95 (%) 97.69 ± 1.53 98.89 ± 0.78 0.000 V95 (%) 98.95 ± 1.29 99.13 ± 0.73 0.423
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completion of radiotherapy.Acute toxicity
Overall, the regimen was tolerated. All patients completed
at least 2 courses neoadjuvant chemotherapy, and 30
(93.7%) patients completed 3 planned courses. Chemo-
therapy dosage was decreased in 17 (53.1%) patients due
to severe adverse events, including 9 patients in the sec-
ond course and 8 in the third course.
The most commonly severe (grade 3–4) haematological
and nonhaematological adverse events were neutropenia
(24 patients; 75%) and Xerostomia (9 patients; 28.1%).
Grade 3–4 adverse events of neoadjuvant chemotherapy
were listed in Table 3. No grade 5 toxicity occurred.
The median course of concurrent chemotherapy was
4 (range 2-6). The number of patients who finished at
least 5 or 4 courses of concurrent chemotherapy totaled
16 (50.0%) and 21 (65.6%), respectively. All patientsTable 2 Dosimetry comparisons of serial structures and paral
Variable Replanned Not replanned P value
Brain stem
D1 (Gy) 56.45 ± 3.33 57.31 ± 5.65 0.209
D5 (Gy) 52.76 ± 3.28 54.09 ± 4.34 0.001
D10 (Gy) 50.38 ± 3.36 51.40 ± 4.36 0.023
Optic chiasm
D1 (Gy) 58.55 ± 7.79 62.76 ± 7.64 0.000
D5 (Gy) 57.86 ± 7.63 62.00 ± 7.47 0.000
D10 (Gy) 57.41 ± 7.66 61.30 ± 7.58 0.000
Optic nerve
D1 (Gy) 57.77 ± 8.95 61.74 ± 8.45 0.000
D5 (Gy) 56.31 ± 8.96 60.29 ± 8.49 0.000
D10 (Gy) 54.83 ± 9.15 58.75 ± 8.72 0.000
Abbreviations: D1 dose to 1% of the volume, D5 dose to 5% of the volume, D10 dos
the volume, Dmean mean dose per fraction.experienced some degree of acute toxicity during con-
current chemoradiotherapy (Table 3).
Survival rates
A total of 5 failures were observed during follow up, in-
cluding 3 patients with local recurrence alone and 2 pa-
tients with distant metastasis alone. The 2-year PFS was
77.7% (95%CI, 57.6% to 96.4%), LPFS 88.2% (95%CI,
72.9% to 100.0%), RPFS 100.0%, DMFS 89.6% (95%CI,
75.9% to 100.0%) and OS 100.0%, respectively. Figure 3
shows the Kaplan-Meier curves for LPFS.
Discussion
Patients with extensive local disease infiltrating or abutting
the critical tissues are one of the most difficult groups to
treat. To maximize their chance of cure and spare the crit-
ical normal, we used neoadjuvant chemotherapy in an at-
tempt to shrink the primary tumor and replanning during
concurrent chemotherapy with IMRT technique for wider
margin. The primary objective of this study we arelel structures
Variable Replanned Not replanned P value
Temporal lobe
D-Mean (Gy) 20.20 ± 3.26 21.48 ± 3.86 0.000
D50 (Gy) 14.87 ± 4.75 16.05 ± 5.23 0.000
D80 (Gy) 6.53 ± 2.66 6.96 ± 2.88 0.000
Inner ear
D-Mean (Gy) 52.96 ± 4.94 53.41 ± 5.23 0.018
D-50 (Gy) 52.83 ± 5.34 53.98 ± 5.81 0.009
D-80 (Gy) 45.82 ± 5.43 46.28 ± 5.73 0.030
Middle ear
D-Mean (Gy) 59.24 ± 5.53 59.51 ± 5.76 0.097
D-50 (Gy) 59.52 ± 5.81 60.00 ± 6.09 0.009
D-80 (Gy) 54.39 ± 6.71 54.79 ± 6.97 0.027
e to 10% of the volume, D50 dose to 50% of the volume, D80 dose to 80% of
Table 3 Grade 3–4 treatment-related acute adverse events
During neoadjuvant chemotherapy During concurrent chemoradiation
Event Grade 3 Grade 4 Grade 3 Grade 4
Hematological
Leukopenia 15(46.8%) 3(9.3%) 7(21.8%) 1(3.1%)
Neutropenia 6(18.7%) 18(56.2%) 2(6.2%) 4(12.5%)
Neutropenia fever 3(9.3%) 0(0.0%) 0(0.0%) 0(0.0%)
Thrombocytopenia 0(0.0%) 0(0.0%) 3(9.3%) 1(3.1%)
Anemia 0(0.0%) 0(0.0%) 2(6.2%) 0(0.0%)
Non-hematological
Fatigue 4(12.5%) 0(0.0%) 4(12.5%) 0(0.0%)
Nausea/vomiting 4(12.5%) 0(0.0%) 4(12.5%) 0(0.0%)
Ototoxicity 0(0.0%) 0(0.0%) 0(0.0%) 0(0.0%)
Diarrhea 0(0.0%) 0(0.0%) 0(0.0%) 0(0.0%)
Liver dysfunction 0(0.0%) 0(0.0%) 0(0.0%) 0(0.0%)
Kidney dysfunction 0(0.0%) 0(0.0%) 0(0.0%) 0(0.0%)
Stomatitis 1(3.1%) 0(0.0%) 8(25%) 0(0.0%)
Dermatitis - - 1(3.1%) 0(0.0%)
Xerostomia - - 9(28.1%) 0(0.0%)
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ical normal tissue of neoadjuvant chemotherapy and
replanning IMRT. The second objective addressed the effi-
cacy of this treatment strategy. Our results suggest that
neoadjuvant chemotherapy and replanning IMRT help to
ensure safe does to normal structures for NPC with intra-
cranial invasion. The doses to many critical normalFigure 3 Kaplan–Meier estimators of local progression-free survival (Lstructures were significantly decreased. Two-year clinical
outcomes were encouraging.
Radiation therapy in concurrent with cisplatin based
chemotherapy is the standard treatment of choice for T3/
4 and/or N +NPC [15-17]. The role of neoadjuvant
chemotherapy is controversy. The results of phase III trials
and meta-analysis have demonstrated that neoadjuvantPFS) for NPC patients.
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metastases, without benefit on OS for locoregional ad-
vanced NPC. However, none of the trials used concurrent
chemotherapy. The reasons that neoadjuvant therapy has
failed to demonstrate OS efficacy may possibly be due to
inadequate neoadjuvant chemotherapy intensity or efficacy
and inadequacy of the local therapies. So, combining more
effective neoadjuvant chemotherapy with concurrent che-
moradiotherapy is hypothesized to be a promising strategy.
New combinations, such as TPF regimene (docetaxel or
paclitaxel, platinum, and 5-FU) have been shown to be su-
perior to standard PF regimen (platinum, and 5-FU) for
squamous cell carcinoma of the head and neck (HNSCC)
in numerous phase III trials. And several studies [11,12,18]
on neoadjuvant setting involving taxane provided impres-
sive results in NPC patients. A randomized phase II trial
[12] published in 2009 studied the stage III ~ IVB NPC pa-
tients treated with or without neoadjuvant chemotherapy
using docetaxel and cisplatin (TP regimen) followed by
concurrent cisplatin chemotherapy and radiation. The re-
searchers demonstrated a significant improvement in
overall survival in patients treated with neoadjuvant
TP chemotherapy: The 3-year OS rate of 94.1% after
neoadjuvant chemotherapy followed by chemoradiation,
as compared to 65% after chemoradiation alone. In
2007, 2 prospective phase II clinical trials respectively
for stage III and non-metastatic stage IV NPC were ini-
tiated to evaluate the efficacy and safety of induction
TPF chemotherapy followed by concurrent CRT using
3D-CRT or IMRT in our hospital. The overall response
rate in the primary site and neck region were 97.4%
(CR 24.1%) and 100% (CR 12.1%) after completion of
neoadjuvant chemotherapy. With median follow-up
times of 32.9 months, the 3-year overall survival rates
were 94.8% (95% CI 87.6%-100%) and 90.2% (95% CI
81.8%-98.6%) for stage III and IVA/B NPC patients, re-
spectively. Sixty-four patients in this reporting group
were included in the prospective phase II clinical trial
for stage IV NPC. The overall response rate and the OS
of this retrospective study were similar with that of our
prospective studies and Hui’s [12] study.
It was reported in several previous studies that many
patients undergoing RT for HNSCC or NPC had signifi-
cant anatomic changes during their course of treatment,
including shrinking of the primary tumor or nodal
masses and in overall body weight loss, especially for pa-
tients with large lymph node in the neck [9,10,19]. Thus,
repeat CT imaging and IMRT replanning during the
course of IMRT for selected patients are essential to
identify dosimetric changes and to ensure adequate
doses to target volumes and safe doses to normal tissues
and recommendatory for specific patients [4,20]. How-
ever, none of these reports have studied anatomic and
dosimetric changes in patients receiving neoadjuvantchemotherapy. Anatomic changes in the external con-
tour and shape are the main reasons for the repeat CT.
And shrinkage of the primary tumor or nodal masses is
the main reason for anatomic changes. The objective re-
sponses were 93.7% (CR 15.6%) and 100% (CR 12%) to the
primary tumor and cervical lymph nodes after neoadjuvant
chemotherapy in this reporting group patients, namely al-
most all patients developed significant tumor shrinkage be-
fore IMRT. On the one hand, the shrinkage of the tumor
facilitated the IMRT planning; on the other hand, shrink-
age of the primary tumor or nodal masses and anatomic
changes in the external contour and shape during the latter
IMRT might be minimal, which makes repeat CT imaging
during radiotherapy not as necessary as we expected in
previous reports. Moreover, the implementation of repeat
CT imaging increased physician time spent in re-
contouring normal structures and cost to patients. As a re-
sult, we did replanning IMRT without repeat CT imaging
for our patients.
Our dosimetric results showed that IMRT replanning
was beneficial to ensure safe doses to normal structures
for patients with intracranial invasion NPC. All IMRT
plans provided good coverage of the target volumes. With
replanning during IMRT, the doses to critical normal
structures (brain stem, optic chiasm, optic nerve, inner
ear, middle ear) were significantly decreased (Table 2). De-
creased doses to critical normal structures may help to al-
leviate late toxicities. Due to the relatively short follow-up
time in this reporting, the late toxicities need longer
follow-up and will be the important clinical outcomes in
our update report.
One important issue arising from our study is how to
delineate tumor volumes. It is unknown whether or not it
is safe (in terms of local-regional control) to contour GTV
based on MRI scans after the neoadjuvant chemotherapy
and decrease the size of the GTV during the course of
fractionated radiotherapy for NPC. For our group patients,
initial GTV not only included all visible tumors and/or en-
larged regional lymph nodes as determined by contrast-
enhanced MRI after the neoadjuvant chemotherapy, but
also the invaded skull base showed on MRI before
neoadjuvant chemotherapy with caution. Hansen et al.
[20] chose to maintain the size of the original GTV when
contouring the GTV on the anatomy of the second CT
scans. Zhao et al. [21] chose to adapt the GTV to the ob-
served tumors or lymph nodes volumes on the anatomy of
the second CT scans, but maintain the size of the original
CTV. We intentionally chose to maintain the size of the
GTV and CTV as possible as we can when contouring the
GTV-P2 and CTV-H2 although the tumor shrunk during
radiotherapy. We reduce the target volumes unless there
is no safe margin between the target and the critical
normal tissues (Figures 1 and 2). As far as T4 NPC is
concerned, the 2-year LRFS (88.2%) in our group is
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P2, which suggested that this target contouring was feas-
ible, but need further confirmed.
In conclusion, neoadjuvant chemotherapy and replan-
ning IMRT according to tumor shrinkage during the
course of IMRT is essential to ensure adequate doses to
safe doses to normal tissues for intracranial invasion NPC.
This treatment strategy is well tolerated and produces en-
couraging outcome. However, it remains to be proven in
the long-term outcomes and late complications.
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